AbbVie Dirección
Dirección controles de criterios 2/4
El CEO de AbbVie's es Rick Gonzalez , nombrado en Jan 2013, tiene una permanencia de 11.25 años. compensación anual total es $25.66M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.031% de las acciones de la empresa, por valor de $91.77M. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 11.3 años, respectivamente.
Información clave
Rick Gonzalez
Chief Executive Officer (CEO)
US$25.7m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 11.3yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 1.5yrs |
| Promedio de permanencia en la Junta Directiva | 11.3yrs |
Actualizaciones recientes de la dirección
Recent updates
AbbVie's Q1: Positive Surprise
Apr 26AbbVie: Great To Be Proven Wrong - Still Not A Buy
Apr 14AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
Apr 08AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
Mar 08AbbVie: Things Are Getting Clearer
Feb 05AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)
Jan 30AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55
Jan 05
AbbVie: Time To Lock In Gains (Rating Downgrade)
Jan 03AbbVie Vs. GSK: Dual Dominance In Pharma
Dec 23AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's
Dec 124.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
Nov 29AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
Nov 28AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
Nov 21AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55
Oct 30AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results
Oct 30AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
Oct 23AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
Oct 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$26m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$26m | US$2m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$24m | US$2m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$24m | US$2m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$22m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$5b |
| Dec 31 2018 | US$21m | US$2m | US$6b |
| Sep 30 2018 | n/a | n/a | US$8b |
| Jun 30 2018 | n/a | n/a | US$6b |
| Mar 31 2018 | n/a | n/a | US$6b |
| Dec 31 2017 | US$23m | US$2m | US$5b |
Compensación vs. Mercado: La compensación total de Rick($USD25.66M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.
CEO
Rick Gonzalez (69 yo)
11.3yrs
Permanencia
US$25,661,972
Compensación
Mr. Richard A. Gonzalez, also known as Rick, serves as Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of Phar...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$25.66m | 0.031% $ 89.8m | |
| President & COO | 1.9yrs | US$14.44m | 0.0056% $ 16.2m | |
| Executive VP & CFO | 1.9yrs | US$10.19m | 0.00087% $ 2.5m | |
| Executive VP & COO | less than a year | US$9.30m | 0.013% $ 37.0m | |
| Executive VP & Chief Commercial Officer | no data | US$15.35m | 0.0035% $ 10.2m | |
| Senior VP & Chief Scientific Officer of Global Research | no data | sin datos | 0.0061% $ 17.6m | |
| Senior Vice President of Investor Relations | no data | sin datos | sin datos | |
| Executive VP | 1.6yrs | sin datos | 0% $ 0 | |
| Senior VP | less than a year | sin datos | sin datos | |
| Executive VP & Chief Human Resources Officer | no data | US$3.30m | 0.00078% $ 2.3m | |
| Senior VP of AbbVie & President of Oncology | less than a year | sin datos | sin datos | |
| Executive VP and Chief Business & Strategy Officer | 1.3yrs | sin datos | 0.0032% $ 9.2m |
1.5yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ABBV no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$25.66m | 0.031% $ 89.8m | |
| Independent Director | 11.3yrs | US$385.59k | 0.00065% $ 1.9m | |
| Independent Director | 4yrs | US$380.78k | 0.0071% $ 20.5m | |
| Lead Independent Director | 11.3yrs | US$418.94k | 0.0014% $ 4.1m | |
| Independent Director | 11.3yrs | US$394.98k | 0.00090% $ 2.6m | |
| Independent Director | 11.3yrs | US$377.48k | 0% $ 0 | |
| Independent Director | 11.3yrs | US$369.98k | 0.00011% $ 319.0k | |
| Independent Director | 7yrs | US$369.98k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$380.78k | 0% $ 0 | |
| Independent Director | 6yrs | US$359.98k | sin datos | |
| Independent Director | 11.3yrs | US$461.18k | 0.000010% $ 29.0k | |
| Independnet Director | less than a year | sin datos | sin datos |
11.3yrs
Permanencia media
69yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ABBV son experimentados ( 11.3 años antigüedad media).